Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Althea Group is an early-stage investment firm based in the United States, specializing in biotech and healthcare. The firm focuses on providing growth capital and strategic advisory services to startups. Their investment strategy targets companies in the pre-seed and seed stages, with a particular emphasis on genetic medicine and innovative technologies.
Althea Group invests in early-stage companies across sectors such as genetic medicine, cancer therapy, women's health, and digestive health. They provide seed and pre-seed funding, concentrating on technologies that deliver safe and effective solutions. Their investment approach is geared towards supporting the development of next-generation genetic medicines and other innovative healthcare technologies.
Notable portfolio companies include Fusogenix, which focuses on gene delivery technology for COVID-19 treatment; Dieta, a personalized digestive health solution for IBS using data and AI; and RxTransparent, acquired by Inmar Intelligence. Other investments include Sea Monsters, a consumer packaged goods company, and a revolutionary new test for endometriosis aimed at improving diagnosis.
Email info@altheagroup.com with your deck to pitch Althea Group.
Yes, Althea Group often leads investment rounds in the companies they back, particularly in the pre-seed and seed stages.
Althea Group is open to follow-on investments, especially if the company continues to align with their focus on innovative healthcare solutions.
Specific details about the size of Althea Group's current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.